English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Meningococcal meningitis has been a terrifying public health threat in countries of the Sahel and sub-Sahel over the past 100 years. This geographical area has been named the “African meningitis belt”. Older children and young adults are particularly at risk during epidemics. The mortality rate is usually 5% 10%. A serogroup A meningococcal conjugate vaccine was licensed in 2009. Mass campaigns with MenAfriVac covering 1-29 years old have been conducted in several countries with assistance from the GAVI Alliance. Long term health impacts of MenAfriVac can only be determined if strong disease surveillance is in place. The study objective was to estimate the costs of meningitis surveillance in Chad and determine resources needed for implementing district case based surveillance.

Costs of current and improved meningitis disease surveillance in Chad